9 completed, 5 unknown, 2 recruiting, 1 active not recruiting. 9 Phase 2, 6 Phase 3, 3 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Active not recruiting 1, Recruiting 1, Unknown 1 |
| Phase 3 | 6 | Completed 3, Unknown 2, Active not recruiting 1 |
| Not applicable | 3 | Completed 1, Terminated 1, Unknown 1 |
Follow Polycystic liver disease: new trials by email Literature Review of Polycystic liver disease trials Research Report on Polycystic liver disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts aspiration sclerotherapy versus laparoscopic fenestration - Liver Cyst, Polycystic Liver Disease | Not applicable | Unknown | Radboud University Medical Center | 70 | 2022-10-01 | 2023-04-05 |
| A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD CAM2029, Placebo - Polycystic Liver Disease | Phase 2 / Phase 3 | Active not recruiting | Camurus AB | 71 | 2022-06-28 | 2026-06-01 |
| A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease Leuprorelin - Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney | Phase 2 | Recruiting | University Medical Center Groningen | 36 | 2022-06-01 | 2022-11-04 |
| Polycystic Liver Disease Registry (UK) Polycystic Liver Disease | Recruiting | Portsmouth Hospitals NHS Trust | 500 | 2021-01-21 | 2025-12-23 | |
| The Association Between Skeletal Muscle Mass and Severity of Polycystic Liver Disease and Polycystic Kidney Disease Renal artery embolization - Polycystic Kidney Diseases, Polycystic Liver Disease | Unknown | National Taiwan University Hospital | 600 | 2020-09-29 | 2022-01-31 | |
| Automatic Segmentation of Polycystic Liver Anonymized CT examinations, Training (1), Training (2) - Polycystic Liver Disease, Polycystic Hepatorenal Disease | Unknown | Hospices Civils de Lyon | 120 | 2019-04-01 | 2019-05-28 | |
| Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q). PLD-Q - Polycystic Liver Disease | Completed | Mayo Clinic | 594 | 2014-06-01 | 2024-09-19 | |
| Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease Ursodeoxycholic Acid - Polycystic Liver Disease, Polycystic Kidney, Autosomal Dominant | Phase 2 | Completed | Radboud University Medical Center | 34 | 2013-12-01 | 2021-09-23 |
| Pasireotide LAR in Severe Polycystic Liver Disease Pasireotide LAR, Placebo - Somatostatin Analogs, Polycystic Liver Disease | Phase 2 | Completed | Mayo Clinic | 48 | 2012-08-01 | 2020-05-01 |
| Study of Lanreotide to Treat Polycystic Kidney Disease Lanreotide - Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 3 | Unknown | University Medical Center Groningen | 300 | 2012-06-01 | 2017-05-23 |
| Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE) Lanreotide - Polycystic Liver Disease | Completed | Radboud University Medical Center | 43 | 2011-05-01 | 2014-07-09 | |
| Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease Lanreotide Autogel 90 mg and 120 mg - Polycystic Liver Disease | Phase 2 / Phase 3 | Completed | Universitaire Ziekenhuizen KU Leuven | 59 | 2011-03-01 | 2014-07-08 |
| Everolimus and LongActing Octreotide Trial in Polycystic Livers Everolimus, Octreotide LAR - Polycystic Liver Disease | Phase 2 | Completed | Radboud University Medical Center | 44 | 2010-06-01 | 2015-06-29 |
| The Vienna RAP Pilot Study Sirolimus - ADPKD | Not applicable | Completed | Medical University of Vienna | 8 | 2009-11-01 | 2012-07-03 |
| Polycystic Liver Disease in Kidney Transplant Tacrolimus, Sirolimus, Mycophenolate Mofetil - Polycystic Liver Disease | Not applicable | Terminated | Mayo Clinic | 2 | 2009-02-01 | 2013-03-08 |
| Open-Label Extension of LOCKCYST Trial lanreotide - Polycystic Liver Disease, Hepatomegaly | Phase 2 / Phase 3 | Unknown | Radboud University Medical Center | 54 | 2008-04-01 | 2008-11-13 |
| Lanreotide as Treatment of Polycystic Livers Placebo, Lanreotide - Polycystic Liver Disease, Hepatomegaly | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 38 | 2007-10-01 | 2009-02-17 |
| Octreotide in Severe Polycystic Liver Disease Octreotide, Placebo - Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease | Phase 2 / Phase 3 | Completed | Mayo Clinic | 42 | 2007-01-01 | 2012-11-21 |
Polycystic Kidney, Autosomal Dominant (11) · Polycystic Kidney Diseases (4) · Hepatomegaly (3) · Liver Diseases (3) · Abdominal Pain (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Multiple Pterygium Syndrome, Autosomal Dominant (1) · Muscular Atrophy (1)
Abnormalities, Multiple (13) · Ciliopathies (13) · Congenital Abnormalities (13) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (13) · Female Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (13) · Genetic Diseases, Inborn (13) · Kidney Diseases (13) · Kidney Diseases, Cystic (13) · Male Urogenital Diseases (13) · Urogenital Diseases (13) · Urologic Diseases (13) · Polycystic Kidney Diseases (9) · Pathological Conditions, Anatomical (4) · Pathological Conditions, Signs and Symptoms (4)
lanreotide (4) · Sirolimus (2) · Everolimus (1) · Leuprolide (1) · Mycophenolic Acid (1) · Octreotide (1) · Prednisone (1) · Tacrolimus (1) · Ursodeoxycholic Acid (1)
Radboud University Medical Center (6) · Mayo Clinic (4) · University Medical Center Groningen (2) · Camurus AB (1) · Hospices Civils de Lyon (1) · Medical University of Vienna (1) · National Taiwan University Hospital (1) · Portsmouth Hospitals NHS Trust (1) · Universitaire Ziekenhuizen KU Leuven (1)
Netherlands (10) · United States (5) · Belgium (4) · Austria (1) · France (1) · Germany (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Frederik Nevens, MD, PhD (3) · Joost PH Drenth, MD, PhD (3) · Loes van Keimpema, MSc (2) · Ared Wu, MD (1) · Gere Sunder-Plassmann, MD (1) · Joost Drenth, MD (1) · Joost P.H. Drenth (1) · Joost PH Drenth, PhD (1) · Joost PH Drenth, dr. (1) · Marie C Hogan (1) · Marie C Hogan, MD PhD (1) · Marie C. Hogan, M.D., Ph.D. (1) · Melissa Chrispijn, MD (1) · Patrick Dean, M.D. (1) · QI Qian, MD (1)
PMID 39356039, PMID 19646443, PMID 22104015, PMID 22475206, PMID 22773240, PMID 25369108, PMID 26073493, PMID 26166166, PMID 27212247, PMID 27995519, PMID 30422235, PMID 31022403, PMID 32843370, PMID 33779943
UL1RR024150 (1)